Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gyntima Menopause
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Gyntima Menopause (also known as KABP Menopause) is a proprietary three-strain probiotic formula developed by AB-BIOTICS, a subsidiary of the Kaneka Group. The product contains three patented bacterial strains: *Levilactobacillus brevis* KABP 052, *Lactiplantibacillus plantarum* KABP 051, and *Pediococcus acidilactici* KABP 021. It is designed to target the estrobolome—the gut microbiota responsible for metabolizing estrogens—by increasing gut β-glucuronidase activity. This enzymatic action deconjugates estrogens in the gut, allowing for their reabsorption into the bloodstream and thereby modulating systemic estrogen levels. Clinical evidence supports its use in improving menopause-related symptoms such as hot flashes, sleep disturbances, and depressive mood in peri- and postmenopausal women.
- Brand names
- Gyntima Menopause
- Other names
- KABP MenopauseGyntima® Menopause
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on Gyntima Menopause.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gyntima Menopause.